Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01095

Serum IgG is associated with risk of Melanoma in the Swedish AMORIS Study

 Anna Kessler1, 2*, Sam Sollie2,  Mieke Van Hemelrijck2,  Sophia N. Karagiannis2 and Goran Walldius3
  • 1NHS England, United Kingdom
  • 2King's College London, United Kingdom
  • 3Karolinska Institute (KI), Sweden

Background: Relatively little is known about the role of the humoral immune system in melanoma. Tumour infiltrating B cells in melanoma patients have been associated with increased T cell activation in tumours as well as improved patient survival. Immunoglobulins may play an important part in the anti-tumour immune response. We hypothesised that increased levels of pre-diagnostic serum Ig may be protective against melanoma development. Hence, we evaluated associations between pre-diagnostic serum markers of the immunoglobulin A (IgA), IgG and IgM, and risk of developing melanoma in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study.

Methods: Study participants aged ≥20 years with baseline measurements of IgG, IgA and IgM taken between 1985 and 1996 were selected (n=29,876). All individuals were free from melanoma at baseline and 162 study participants developed melanoma during follow up. Cox proportional hazards regression was carried out for medical cut-offs of IgA, IgG and IgM.

Results: Compared to the reference level of 6.10-14.99 g/l, we observed a positive but not significant association with risk of melanoma for those with IgG levels <6.10 g/L [HR: 1.05 (95% CI 0.39-2.86)] and an inverse association for those with IgG levels ≥ 15.00 g/L [HR: 0.60 (95% CI 0.34-1.05); Ptrend = 0.08]. No associations with serum IgA or IgM were identified.

Conclusions: The humoral response might provide a protective role against the development of melanoma, mediated through IgG. Further research is needed to characterise this response which may be exploitable for development of future therapies.

Keywords: Melanoma, AMORIS cohort, Immunoglobin, IgG, humoral immunity, Melanoma risk

Received: 31 Jan 2019; Accepted: 04 Oct 2019.

Copyright: © 2019 Kessler, Sollie, Van Hemelrijck, Karagiannis and Walldius. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Anna Kessler, NHS England, London, United Kingdom,